Your browser doesn't support javascript.
loading
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
West, Malcolm; Kirby, Adrienne; Stewart, Ralph A; Blankenberg, Stefan; Sullivan, David; White, Harvey D; Hunt, David; Marschner, Ian; Janus, Edward; Kritharides, Leonard; Watts, Gerald F; Simes, John; Tonkin, Andrew M.
Affiliation
  • West M; Department of Medicine University of Queensland Brisbane Australia.
  • Kirby A; National Health and Medical Research Council Clinical Trials CentreUniversity of Sydney Sydney Australia.
  • Stewart RA; Green Lane Cardiovascular Service Auckland City HospitalUniversity of Auckland Auckland New Zealand.
  • Blankenberg S; University Heart and Vascular Centre Hamburg Hamburg Germany.
  • Sullivan D; Department of Chemical Pathology Royal Prince Alfred Hospital Sydney Australia.
  • White HD; Green Lane Cardiovascular Service Auckland City HospitalUniversity of Auckland Auckland New Zealand.
  • Hunt D; Cardiology Department Royal Melbourne Hospital Melbourne Australia.
  • Marschner I; National Health and Medical Research Council Clinical Trials CentreUniversity of Sydney Sydney Australia.
  • Janus E; Department of Medicine Western Health Chronic Disease AllianceWestern HealthMelbourne Medical SchoolUniversity of Melbourne Melbourne Australia.
  • Kritharides L; Department of Cardiology Concord Repatriation General HospitalSydney Local Health District Sydney Australia.
  • Watts GF; ANZAC Medical Research InstituteFaculty of MedicineUniversity of Sydney Sydney Australia.
  • Simes J; School of Medicine Faculty of Health and Medical Sciences University of Western Australia Perth Australia.
  • Tonkin AM; National Health and Medical Research Council Clinical Trials CentreUniversity of Sydney Sydney Australia.
J Am Heart Assoc ; 11(5): e020745, 2022 03.
Article in En | MEDLINE | ID: mdl-35179040
ABSTRACT
Background Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long-term or is independent of renal function and other important biomarkers. Methods and Results Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow-up, 6 years) and long-term (median follow-up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR-creatinine, then GFR-creatinine-cystatin C). Over 6 years, in fully adjusted multivariable time-to-event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07-1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19-1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all-cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR-creatinine-cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28-10.20) independently of estimated GFR-creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR-creatinine-cystatin C. Conclusions Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all-cause mortality. Prediction of long-term mortality was independent of improved estimation of GFR. Registration URL https//anzctr.org.au; Unique identifier ACTRN12616000535471.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Disease / Renal Insufficiency / Renal Insufficiency, Chronic / Cystatin C / Myocardial Infarction Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Am Heart Assoc Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Disease / Renal Insufficiency / Renal Insufficiency, Chronic / Cystatin C / Myocardial Infarction Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Am Heart Assoc Year: 2022 Document type: Article
...